RecruitingNCT05090345

A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

Prospective Multi Center Study of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS)


Sponsor

Duke University

Enrollment

500 participants

Start Date

Nov 19, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.


Eligibility

Min Age: 0 YearsMax Age: 26 Years

Inclusion Criteria3

  • Children, adolescents and young adults (AYA) 0-26 years of age undergoing HSCT.
  • Recipients of autologous and allogeneic HSCT.
  • Any preparative regimen.

Exclusion Criteria2

  • Any patient who does not consent/assent to participation.
  • Any patient for whom 5 mL blood sample(s) drawn at specified intervals would pose any more than minimal risk, as defined by institutional guidelines and at discretion of treating physician will be ineligible for biorepository banking.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiorepository Trial

participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.


Locations(3)

Mayo Clinic

Rochester, Minnesota, United States

Duke University

Durham, North Carolina, United States

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05090345


Related Trials